Tag Archives: Fibromyalgia

Research Identifies a Potential New Path to Developing a Treatment for Chronic Pain

Los Angeles, September 8, 2015 – Targeted Medical Pharma to present new chronic pain research that reveals significant nervous system abnormalities among patients suffering from Fibromyalgia, at the 2015 PainWeek national conference in Las Vegas, Nevada. The study looked at 329 Fibromyalgia patients and 58 control patients all of whom wore Holter monitors for a 24 hour period to measure nervous system activity. The results of this study showed that patients with Fibromyalgia experience a significant decrease in both nighttime parasympathetic nervous system (PNS) activity and daytime sympathetic Continue reading →

Targeted Medical Pharma to Present at Sachs Associated 14th Annual Biotech in Europe Forum for Global Partnering and Investment

Los Angeles, September 16, 2014 — Targeted Medical Pharma (OTCQB:TRGM), today announced that William Shell, M.D., Chairman, CSO and CEO  is scheduled to present the latest company information regarding the advances in therapeutic nutrition and medical foods technology, at the 14th Annual Biotech in Europe Forum at the Congress Center in Basel, Switzerland. The presentation is scheduled for September 30th, 2014 at 11:45 am in the Lima Room. Dr. Shell will also be a panelist in the discussion regarding advancements in Neuroscience at 3:30 pm. Additional information Continue reading →

Targeted Medical Pharma to Present at the Third Annual Marcum MicroCap Conference

Los Angeles, CA –  May 23, 2014 – Targeted Medical Pharma (OTCQB: TRGM), a leader in the medical food manufacturing sector, announced today that it will be a featured presenter at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel. The Company’s presentation by William Shell M.D., Chief Executive Officer and Chief Science Officer, is scheduled to begin at 11:30 a.m. ET. The annual Marcum MicroCap Conference is a signature showcase for superior quality, Continue reading →

Targeted Medical Pharma Announces Completion of Sales Agreement with Pacific Medical, Inc

Agreement Provides the Company with the Ability to Rapidly Expand Sales and Education Programs Los Angeles, CA, January 10, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), reported on the completion of an independent sales agreement with Pacific Medical, Inc., a distributor of durable medical equipment in the United States who specializes in orthopedic, rehabilitation, surgery and sports medicine. The non-exclusive agreement will allow Targeted Medical Pharma to expand medical food sales and education programs to licensed healthcare professionals in Northern California and Northern Nevada Continue reading →

Targeted Medical Pharma to Present at the Demy-Colton 2014 BIOTECH Showcase

Targeted Medical Pharma to Present at the Demy-Colton 2014 BIOTECH Showcase Los Angeles, January 9, 2014 — Targeted Medical Pharma, announced that members of its executive team are scheduled to present the latest information regarding medical foods at the sixth annual Biotech Showcase™ on January 14, 2014 at 4:00 p.m. PST, at the Parc 55 Wyndham Hotel in San Francisco, CA. Management also will conduct one-on-one meetings with investors from January 13-15, 2014. Biotech Showcase is an investor and partnering conference devoted to providing private Continue reading →

Targeted Medical Pharma to Present at 2013 Aegis Capital Healthcare Conference

Los Angeles, CA, September 24th, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced that the company’s CEO and Chief Science Officer William Shell, M.D. along with President and Chief Operating Officer, David Silver M.D., will be presenting at the Aegis Capital 2013 Healthcare Conference being held at The Encore at Wynn Hotel in Las Vegas, Nevada on Friday, September 27, 2013 at 11:30 a.m. in Room 1. The conference will feature more than 45 healthcare companies from around the world and will feature presentations Continue reading →

Targeted Medical Pharma’s President and COO David Silver Comments on Study Showing µ-Opiod Receptors Impaired in Fibromyalgia Patients

Los Angeles, CA, May 31, 2013 — David Silver, M.D., President and Chief Operating Officer at Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and distributes prescription medical foods, issued the following statement regarding a University of Michigan study highlighted in Pain Medicine News demonstrating the connection between μ-opioid receptor binding and the brain’s response to fibromyalgia pain: “The University of Michigan study confirms widespread consensus within the medical community that fibromyalgia patients respond poorly to narcotics. Additionally, there is no medical evidence Continue reading →

Physician Therapeutics Presents Data on Medical Food Theramine® at Scientific Conferences

Los Angeles, September 27, 2012 — Physician Therapeutics, a division of Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and distributes prescription medical foods to physicians, pharmacies and skilled nursing facilities, will present data examining the effectiveness of its medical food Theramine® and low dose ibuprofen for the management of chronic back pain at several upcoming scientific conferences. The scientific poster titled, “Theramine versus ibuprofen for the safe and effective management of chronic low back pain and inflammation,” was first presented on September Continue reading →